209 related articles for article (PubMed ID: 24752260)
1. Population pharmacokinetic analysis of piperacillin in burn patients.
Jeon S; Han S; Lee J; Hong T; Paek J; Woo H; Yim DS
Antimicrob Agents Chemother; 2014 Jul; 58(7):3744-51. PubMed ID: 24752260
[TBL] [Abstract][Full Text] [Related]
2. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
Felton TW; Hope WW; Lomaestro BM; Butterfield JM; Kwa AL; Drusano GL; Lodise TP
Antimicrob Agents Chemother; 2012 Aug; 56(8):4087-94. PubMed ID: 22585219
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.
Tamme K; Oselin K; Kipper K; Tasa T; Metsvaht T; Karjagin J; Herodes K; Kern H; Starkopf J
Acta Anaesthesiol Scand; 2016 Feb; 60(2):230-40. PubMed ID: 26830215
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
Chen R; Qian Q; Sun MR; Qian CY; Zou SL; Wang ML; Wang LY
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):363-72. PubMed ID: 25894901
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB
J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
Cojutti PG; Morandin E; Baraldo M; Pea F
Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
[TBL] [Abstract][Full Text] [Related]
10. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z
Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.
Sukarnjanaset W; Jaruratanasirikul S; Wattanavijitkul T
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):251-261. PubMed ID: 30963365
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Roger C; Udy AA; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052849
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
Cheatham SC; Fleming MR; Healy DP; Chung CE; Shea KM; Humphrey ML; Kays MB
Int J Antimicrob Agents; 2013 Jan; 41(1):52-6. PubMed ID: 23228881
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
[TBL] [Abstract][Full Text] [Related]
18. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.
Felton TW; Roberts JA; Lodise TP; Van Guilder M; Boselli E; Neely MN; Hope WW
Antimicrob Agents Chemother; 2014 Jul; 58(7):4094-102. PubMed ID: 24798288
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
